Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Obstructive sleep apnoea and metabolic impairment in severe obesity

M. Gasa, N. Salord, A.M. Fortuna, M. Mayos, N. Vilarrasa, J. Dorca, J.M. Montserrat, M.R. Bonsignore, C. Monasterio
European Respiratory Journal 2011 38: 1089-1097; DOI: 10.1183/09031936.00198810
M. Gasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mgasa@bellvitgehospital.cat
N. Salord
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.M. Fortuna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Mayos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Vilarrasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Dorca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.M. Montserrat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.R. Bonsignore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Monasterio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Obstructive sleep apnoea (OSA) seems to worsen metabolism. This effect has not been evaluated in morbid obesity (MO). We hypothesised that the metabolic profile is more impaired in MO patients with OSA than in those without, and investigated whether any specific metabolic dysfunction is related to OSA in MO.

A prospective multicentre cross-sectional study was conducted in consecutive subjects before bariatric surgery. OSA was defined as apnoea/hypopnoea index (AHI) ≥15 by overnight polysomnography. Anthropometrical, blood pressure (BP) and fasting blood measurements were obtained the morning after. Metabolic syndrome (MetS) was defined according to National Cholesterol Education Program Adult Treatment Panel III modified criteria.

159 patients were studied: 72% were female and 72% had OSA. MetS prevalence was 70% in OSA versus 36% in non-OSA (p<0.001). As AHI severity increased, metabolic parameters progressively worsened, even in those without type 2 diabetes (DM2). AHI was independently associated with systolic and diastolic BP, triglycerides and the percentage of glycosylated haemoglobin (HbA1c) in the total sample, and with systolic BP, high-density lipoprotein cholesterol and HbA1c in those samples without DM2. OSA increased the adjusted odds ratio of having MetS by 2.8 (95% CI 1.3–6.2; p=0.009).

In MO, OSA is associated with major metabolic impairment caused by higher BP and poorer lipid and glucose control, independent of central obesity or DM2.

  • Metabolic index
  • metabolic syndrome
  • morbid obesity
  • obstructive sleep apnoea

Metabolic abnormalities, whether assessed as metabolic syndrome (MetS) [1] or as their single components (central obesity, impaired glucose metabolism, hypertension, hypertriglyceridaemia and lower high-density lipoprotein cholesterol (cHDL)) have been shown to increase cardiovascular (CV) morbidity and mortality [2–5]. Central obesity seems to play a crucial role in the origin of metabolic disruption, but many other mechanisms have also been considered responsible [6]. Recent reports have suggested that obstructive sleep apnoea (OSA) may worsen the effect of obesity on cardiometabolic risk and that it could represent an additional burden on the metabolic dysfunction associated with obesity [7, 8].

The mechanisms through which OSA may worsen metabolism are complex. It may trigger several pathological mediating pathways (sympathetic activation, neurohumoral changes, glucose homeostasis disruption, inflammation and oxidative stress) through chronic intermittent hypoxia (CIH), and these may ultimately cause deterioration in the metabolic function [9, 10]. Animal studies have shown reduced insulin resistance and plasma lipids, as well as increased blood pressure (BP), after exposure of lean and obese animals to CIH [11], but data in humans are more scarce.

Obesity is the main confounding factor in the investigation of the association between OSA and metabolic dysfunction [12]. Most previous reports have excluded subjects with morbid obesity (MO), possibly because the effect of OSA is expected to be little or absent in this subpopulation, due to extreme obesity. Conversely, MO patients could have a higher CV risk compared with non-MO subjects, because of the high prevalence of both metabolic dysfunction [13, 14] and OSA [15, 16]. Therefore, investigating this association in MO should contribute to a better understanding of the relative interaction between OSA, MO and metabolic dysfunction.

We hypothesised that, in a cohort of consecutive MO patients enrolled in a bariatric surgery programme, the metabolic profile is more impaired in those with OSA than in those with no OSA. Furthermore, we attempted to detect whether there is any specific metabolic dysfunction pattern related to OSA, and whether the overall CV risk increases in parallel with OSA severity in the morbidly obese.

METHODS

Subjects and protocol

Consecutive patients prospectively included in the obesity surgery programme were studied in the corresponding Sleep Units from January 2009 through February 2010. The study protocol was approved by the local ethical committee of each hospital (PR052/08, 07/064/797, PI080277). All participants gave their informed written consent.

Inclusion criteria were the same as those for the obesity surgery programme: aged 18–60 yrs and a body mass index (BMI) of ≥40 kg·m−2 or ≥35 kg·m−2 with comorbidity related to obesity (resistant hypertension, established heart disease, severe degenerative osteoarthritis, respiratory failure). The following patients were excluded: those with known OSA and prior continuous positive airway pressure (CPAP) treatment, unstable CV conditions, acute or chronic inflammatory diseases during the previous 6 months, chronic immunosuppressant therapy, severe cognitive or psychiatric disorders, chronic obstructive pulmonary disease (COPD) [17], pregnancy or past or current history of alcohol abuse, and those who refused to give their consent.

Each participant completed a detailed questionnaire on medical history, cardiovascular risk factors and current medication. Exercise level and sleep duration were recorded by a self-administered International Physical Activity Questionnaire [18] and a sleep diary for 15 consecutive nights. Anthropometric characteristics included BMI, neck circumference (at the level of the laryngeal prominence), waist circumference (WC; measured midway between the lower rib and the iliac crest), waist/hip ratio and percentage of body fat mass measured by electrical bioimpedance (BIA 101; Akern Bioresearch, Florence, Italy). Clinical BP was measured by a standard mercury sphygmomanometer while the subject was seated at rest, and taken as the mean value of at least two measurements separated by 5 min; an additional measurement was made if there was a difference of >5 mmHg between the two [19]. Respiratory functional assessment included forced spirometry and arterial blood gas analysis, taken with the subject seated breathing room air.

Sleep study

OSA was determined by a full overnight polysomnography (PSG). PSG interpretation was assessed according to standard criteria [20], as described in E1 of the online supplementary material.

As few morbidly obese patients were expected to show an apnoea/hyponoea index (AHI) <5 events·h−1 [16], an AHI cut-off of 15 events·h−1 was chosen to define the presence of OSA by the study design. The degree of nocturnal desaturation was assessed by the mean percentage of sleep time with arterial oxygen saturation measured by pulse oximetry <90% (time Sp,O2 <90%). Excessive daytime sleepiness (EDS), quantified by the Epworth sleepiness scale (ESS), was defined as an ESS score ≥10.

Blood measurements and MetS definition

The morning after PSG, a venous blood sample was obtained from all patients in fasting conditions and an oral glucose tolerance test (OGTT) was performed, except in those with previously known type 2 diabetes (DM2). Fasting blood glucose (FBG), percentage of glycosylated haemoglobin (HbA1c), total cholesterol, triglycerides, cHDL, low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol levels were determined with standard laboratory methods. Patients were classified according to the OGTT: normal glucose tolerance (post-load glucose <7.8 mmol·L−1), impaired glucose tolerance (post-load glucose 7.8–11.1 mmol·L−1) and established DM2 (post-load glucose ≥11.1 mmol·L−1) [21].

MetS was defined in accordance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III modified criteria [1] as the presence of three or more of the following: WC ≥88 cm in females, ≥102 cm in males; high BP as systolic ≥130 and/or diastolic ≥85 mmHg or antihypertensive treatment; high FBG as ≥5.6 mmol·L−1 or anti-diabetic treatment; high triglycerides as ≥1.7 mmol·L−1 or lipid-lowering treatment; reduced cHDL as <1.3 mmol·L−1 in males and <1 mmol·L−1 in females or lipid-lowering treatment. Metabolic index was established as the number of individual MetS components for each patient.

Cardiovascular risk assessment in the AHI categories

The Framingham cardiac risk score was applied to estimate the CV risk [22] in the different AHI categories. The scores consider sex, age, total cholesterol, cHDL, systolic BP and smoking, and they were used to predict the 10-yr risk of coronary events in the AHI categories.

Sample size

Power calculations indicated that 39 subjects were needed in each group to detect a difference of at least 0.32 in MetS prevalence between OSA and non-OSA, based on prior studies reporting high prevalence of MetS and OSA in MO [23] and similar MetS prevalence difference depending on OSA status [24], assuming an α risk of 0.05 and a β risk of 0.20.

Statistical methods

Data were expressed as mean±sd, median (interquartile range) or percentage for parametric, nonparametrical and categorical data, respectively. The bivariate comparisons were evaluated using the Chi-squared (categorical), t- (parametric) or Mann–Whitney (nonparametric) unpaired tests.

Multiple comparisons were evaluated using the Chi-squared test (categorical), ANOVA with Scheffe post hoc analysis (parametric) and the Mann–Whitney test, applying the Bonferroni method when significant differences were found by the Kruskal–Wallis test (nonparametric). The adjusted linear regression model studied the association between AHI and individual measures of metabolic dysfunction. Logistic regression assessed the relationship between MetS and OSA (AHI ≥15). The association results were summarised using unadjusted and adjusted odds ratios and β coefficients with their 95% confidence intervals. A p-value of <0.05 was considered statistically significant. SPSS version 15 software (SPSS Inc., Chicago, IL, USA) was used for all the analyses.

RESULTS

A total of 174 consecutive patients were evaluated. 15 patients were excluded due to inflammatory disease (n=8), COPD (n=3), pregnancy (n=1), immunosuppressant therapy (n=1) and refusal to participate (n=2). Thus, we studied 159 patients: 44 non-OSA and 115 OSA. The mean age was 43±10 yrs, the mean BMI was 46.1±5.8 kg·m−2 and 72% of them were female.

OSA versus non-OSA group

OSA subjects were older, had a larger neck and WC, and had a nonsignificant trend toward a higher BMI (table 1). No differences were observed in sex predominance and OGTT categories. When stratifying by sex, the level of physical activity did not differ between OSA and non-OSA subjects (data not shown). In terms of comorbidities, hypertension and diabetes were reported more frequently by OSA than by non-OSA patients (hypertension 48% versus 21%, p=0.002, diabetes 24% versus 11%, p=0.057, respectively). With regard to medication, angiotensin receptor antagonists and oral hypoglycaemic agents were prescribed more in the OSA than in the non-OSA group (12% versus 0%, p=0.015, and 22% versus 7%, p=0.027, respectively).

View this table:
  • View inline
  • View popup
Table 1– General and sleep characteristics of the study cohort

Table 1 also shows the main sleep characteristics of the total sample, and according to the presence/absence of OSA. Self-reported sleep duration was longer in OSA than in non-OSA but the PSG total sleep time was similar in both groups. OSA subjects had worse sleep parameters in terms of nocturnal oxygen desaturation levels and arousal index, but with no differences in the sleep stage percentages or in the level of EDS, according to the ESS.

Metabolic variables according to AHI categories

OSA patients had a more impaired metabolic profile than non-OSA patients (table 2). They had higher levels of systolic and diastolic BP, FBG, HbA1c and triglycerides, and lower levels of cHDL. Moreover, as the severity of OSA increased according to AHI categories, a progressive significant worsening of individual metabolic parameters was found and the metabolic index deteriorated. The Framingham cardiac risk score also increased with the OSA categories (fig. 1).

View this table:
  • View inline
  • View popup
Table 2– Metabolic syndrome components and others metabolic variables according to obstructive sleep apnoea (OSA) categories
Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

The Framingham cardiac risk score [22] was applied to estimate the 10-yr risk of coronary events in the different apnoea/hypopnoea index (AHI) categories. ANOVA with Scheffe post hoc analysis was used for comparisons between obstructive sleep apnoea (OSA) categories. CHD: coronary heart disease. p <0.005.

The overall prevalence of MetS was 60%, but was twice as high in the OSA group compared with the non-OSA group (70% versus 36%, p<0.001). The prevalence of each individual MetS component was also higher in the OSA group but did not reach significance for reduced cHDL (41% versus 27%, p=0.112) (fig. 2).

Figure 2–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2–

The presence of obstructive sleep apnoea (OSA) was considered when the apnoea/hypopnoea index was ≥15 events·h−1. The metabolic syndrome (MetS) definition and its components were based on National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III modified criteria [1]. The Chi-squared test was used for comparisons. BP: blood pressure; FBG: fasting blood glucose; cHDL: high-density lipoprotein cholesterol; TG: triglycerides.

We also examined the relationship between individual metabolic parameters and OSA markers by linear regression analysis (table 3). In the unadjusted model, all metabolic parameters were associated with AHI and time Sp,O2 <90% (data not shown). After adjusting for age, sex, smoking and BMI, the association with AHI remained significant for systolic BP, diastolic BP, triglycerides and Hb1Ac, but was lost for FBG and cHDL. When adding WC to the adjustment, the associations did not change. Associations with oxygen desaturation index ≥ 3% (ODI3%) followed a similar pattern to those with AHI (data not shown). In contrast, when the same analysis was performed with time Sp,O2 <90%, only Hb1Ac and triglycerides were significant; but after adjusting for WC, the association only remained significant for HbA1c.

View this table:
  • View inline
  • View popup
Table 3– The association of metabolic parameters with obstructive sleep apnoea severity evaluated as apnoea/hypopnoea index (AHI) and time for arterial oxygen saturation measured by pulse oximetry (Sp,O2) <90% total sleep time (TST) in the entire group

Table 4 summarises the results of binary logistic regression to assess the association of OSA and MetS in MO patients. The occurrence of OSA was defined as AHI ≥15, and the severity of nocturnal hypoxia by cumulative time at Sp,O2 <90% as ≥4.65% (as the median sample value). We also assessed the combination of both. After adjusting for age, sex, BMI and smoking, OSA increased the odds of having MetS threefold. The BMI did not appear to contribute to the association since its exclusion during the statistical analysis did not change the results (data not shown).

View this table:
  • View inline
  • View popup
Table 4– The association of metabolic syndrome with obstructive sleep apnoea (OSA) in the global sample

OSA status according to metabolic variables

When we compared patients with (n=96) and without (n=63) MetS, the prevalence of OSA was significantly higher in the MetS group (83% versus 56%, p<0.001). The distribution of the number of MetS components (according to the metabolic index) significantly shifted toward high values in OSA compared with non-OSA patients (Chi-squared test, p-value 0.002; fig. 3).

Figure 3–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3–

The distribution of the metabolic index according to the obstructive sleep apnoea (OSA) presence. The chi-square test was used for comparisons. MetS: metabolic syndrome. p=0.002.

Subanalysis in patients without known DM2

As MetS is considered a pre-morbid condition for DM2, we repeated the analysis after excluding 33 patients with DM2 (reported in supplementary material E2).

Subanalysis in females

Our sample was composed mainly of females (n=115), thus we repeated the analysis for the female subgroup (reported in supplementary material E3).

DISCUSSION

To our knowledge, this is the first large cross-sectional study focusing on the association of OSA and MetS in MO. In agreement with our hypothesis, MetS was more prevalent, and the metabolic profile more impaired, in morbidly obese patients with OSA than in those without. The metabolic profile progressively worsened with increasing OSA severity, irrespective of sex. This worsening remained even after excluding those patients with DM2. Therefore, even in a population with such a high prevalence of MetS as MO patients, OSA is associated with a worse metabolic profile, suggesting a possible additional contribution to the increased CV risk associated with obesity.

The relationship between OSA and metabolic dysfunction has been studied mostly in moderately obese sleep-referred patient cohorts [9, 24–27], and more recently in specific high cardiovascular risk populations, such as MetS [7, 8, 28], hypertensive [29] and CV disease cohorts [30]. All these data agree that OSA is common in middle-aged moderately obese subjects and is associated with MetS or some of its components, independent of the BMI. We have chosen a different approach by studying severely obese patients who represent the extreme model of association between OSA, MetS and MO. Only a small retrospective study pointed out a higher prevalence of both disorders in the same bariatric cohort [23].

The comparison of OSA and non-OSA patients revealed a double prevalence of MetS (70% versus 36%, p<0.001) and a progressively impaired metabolic profile in line with an increased AHI. Therefore, our data do not reinforce the notion that MO overwhelms the potential contribution of OSA to metabolic aggravation. Moreover, the occurrence of OSA still increased the adjusted odds of having MetS by up to threefold, irrespective of sex. This is a novel contribution because no analysis of the metabolic effect of OSA on MO females has been addressed before (see supplementary material E3). Interestingly, in females it seems necessary to increase whole body fat in order to increase central fat; in contrast, this is not required in males. Also, the percentage of menopause state was higher in OSA, compared with non-OSA females, in keeping with three large cohort studies [31–33]; however, the association between OSA and MetS did not change after adjusting for menopause state and percentage of body fat. Thus, it is plausible to consider that in morbidly obese patients, the metabolic dysfunction may be conferred not only by MO but also by OSA, which does not seem to have a sex-specific effect.

Whether OSA is linked to a specific metabolic pattern has yet to be completely defined. In non-MO cohorts, OSA is associated with various metabolic abnormalities, probably due to the heterogeneity of the samples [24–27, 34, 35]. In the present study, a significant linear association was found between AHI and systolic and diastolic BP, triglycerides and HbA1c after controlling for BMI and WC. Furthermore, even in the subgroup of patients without diabetes, the association remained significant with systolic BP, cHDL and HbA1c. Thus, in MO patients, increasing severity of OSA is associated with metabolic worsening, caused mainly by higher systolic BP, lipid disruption and poorer glucose control, independent of adiposity and other confounders, and irrespective of established DM2.

Hypertension has been widely studied in OSA patients [36]. Recent guidelines on hypertension have recognised OSA as a frequent cause of secondary hypertension [37]. Our findings are consistent with previous large studies pointing to a high prevalence of hypertension among OSA patients [38–40]; more interestingly, a clear deterioration in BP levels in line with increasing OSA category was seen in this MO cohort, and higher BP is independently associated with OSA severity, regardless of sex or the degree of obesity.

With regard to glucose metabolism, most published reports have found a significant association between OSA and hyperglycaemia/insulin resistance/diabetes in moderate obese subjects [35, 41–43]. In the present study, although no differences in FBG or OGTT data were found when comparing the OSA and non-OSA groups, HbA1c was highly associated with OSA markers. So, even in the morbidly obese, our data showed a clear, graded inverse relationship between OSA severity and long-term glucose control, as assessed by HbA1c, after controlling for the degree of obesity and other confounders. This finding was also seen in patients without DM2.

The association between OSA and lipid profile has been investigated less. Overall, there is no definitive evidence regarding the effect of OSA on the lipid profile. The majority of cross-sectional studies are negative [26, 44–46], although some large sample studies found a positive association between OSA and higher triglycerides and lower cHDL [24, 47, 48]. Our data also show, for first time in a cohort of MO patients, an independent association of AHI with higher triglycerides and lower cHDL.

Furthermore, although the Framingham study's generalisation of CV risk in MO patients should be interpreted with caution, our data suggest that OSA may contribute an additional burden to CV morbidity and mortality in this cohort, and it should be controlled in any study evaluating the consequences of MetS in the morbidly obese. Experimental studies in animals and humans have shown intermittent hypoxia to be a major determinant of metabolic dysfunction associated with OSA [49, 50]. In our cohort, OSA compared with non-OSA patients had a greater degree of nocturnal CIH due to higher AHI, time Sp,O2 <90% and arousal index without higher subjective EDS or differences in sleep-stage percentages. Furthermore, AHI was independently associated with most of the individual metabolic parameters, according to the linear regression analysis, whereas time Sp,O2 <90% was independently associated with only HbA1c. This may suggest that OSA contributes to metabolic dysfunction in MO, mostly through CIH. Moreover, adding a greater nocturnal hypoxaemia by means of greater time Sp,O2 <90% to a high baseline AHI leads to greater metabolic dysfunction than a high baseline AHI alone, according to the logistic regression analysis. These findings concur with those observed by Polotsky et al. [51], supporting the “two-hit” model hypothesis to explain the potential role of OSA in the development of steatohepatitis and insulin resistance in severe obesity. MO might act as a “first hit” initiating a metabolic dysfunction, and severe OSA through nocturnal CIH may act as a “second hit” aggravating the disorder. Despite strong evidence from experimental studies demonstrating the role of CIH [11], a definitive causal role of OSA in metabolic impairment in humans cannot be firmly established. In interventional studies, CPAP therapy lowered BP [52], while data on glucose and/or lipid control still appear to be inconclusive [53–57]. Thus, further long-term randomised controlled interventional trials are clearly needed in well-characterised samples, and also in the morbidly obese, in order to address the direction of causality.

As well as being the main energy storage organ, adipose tissue is a highly active tissue involved in the integrated metabolism regulation [58]. Ectopic fat, particularly visceral fat, could adversely modify the metabolism, decreasing the insulin sensitivity in key tissues by a paracrine effect and through the release of adipokines that promote a low-grade pro-inflammatory state [59]. OSA may worsen this state [60] by acting as an additional cardiometabolic burden risk. In the present study, we used WC as an accepted surrogate of visceral adiposity [61]. OSA patients had greater WC and neck circumference compared with non-OSA subjects despite a similar BMI and fat mass percentage, suggesting that OSA is more closely linked to a particular visceral adiposity than to the overall obesity. Conversely, the association of OSA with several metabolic abnormalities remained independent of WC and sex, supporting the notion that OSA may play an additional role in the overall metabolic dysfunction, even in MO. Unfortunately, direct analysis of visceral fat was not possible in this study and thus our findings should be considered approximate. Despite this limitation, these results concur with the hypothesis previously proposed by Vgontzas et al. [62]: visceral fat could progressively worsen MetS and OSA manifestations but OSA may also aggravate MetS through an increase in sympathetic activation, inflammation and insulin resistance that deteriorates the overall metabolic dysfunction.

In our cohort, OSA prevalence was notably high: 72% of patients had an AHI ≥15 and only 2% had an AHI <5. Significantly, most subjects did not complain about EDS (72% of OSA patients had ESS <10), even if they had severe OSA. Although previous studies demonstrated objectively higher EDS in obese patients, compared with healthy non-obese controls, regardless of OSA status [63, 64], the lack of sleepiness measured by EDS is concordant with previous studies evaluating patients before bariatric surgery. This point may reflect the limitations of the EDS in the MO population, as there are other potential cofactors that could affect EDS [65, 66]. Our finding of a lack of subjective sleepiness is clinically relevant, however, as it emphasises the need to perform sleep studies in this specific population, regardless of self-reported symptoms.

With regard to limitations, our cross-sectional study design does not provide cause–effect evidence, although the regression analysis showed an independent association between OSA markers and individual parameters of dysfunction. It would also have been desirable to perform abdominal computed tomography or magnetic resonance imaging to assess the amount of visceral fat, but the subjects did not fit into the machines due to their high body weights. Finally, as discussed, we did not assess objective EDS.

Conclusions

OSA is associated with a more severe metabolic profile in MO patients, independent of age, sex, BMI and smoking, suggesting an important role of OSA, in addition to obesity, in the pathogenesis of metabolic dysfunction in this population. As OSA is a treatable condition, and EDS assessed by ESS is not a good OSA marker in MO, clinicians dealing with obese subjects should appropriately assess OSA in addition to other classic known obesity-related comorbidities, in order to better treat the overall metabolic dysfunction.

M. Clarke assisted with the English expression in versions of the manuscript. The statistical analysis advice was performed by C. Masuet (Dept of Preventive Medicine and Biostatistics, Hospital de Bellvitge, Barcelona, Spain). We thank the Sleep Unit staff, T. Brinquis, P. Garriga and S. Perez (Dept of Respiratory Medicine, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain) for their inestimable collaboration.

Footnotes

  • This article has supplementary material accessible from www.erj.ersjournals.com

  • Support Statement

    This work was supported by: Fondo de Investigación Sanitaria (grant FIS PI080800); Spanish Respiratory Society SEPAR (grant Ayudas a la investigación 249/07]; and Societat Catalana de Pneumologia SOCAP (grants 2052/08; 2052/09).

  • Statement of Interest

    None declared.

  • Received December 23, 2010.
  • Accepted April 7, 2011.
  • ©ERS 2011

REFERENCES

  1. ↵
    1. Alberti KG,
    2. Eckel RH,
    3. Grundy SM,
    4. et al
    . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Lakka HM,
    2. Laaksonen DE,
    3. Lakka TA,
    4. et al
    . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.
    OpenUrlCrossRefPubMedWeb of Science
    1. Ford ES
    . Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–1778.
    OpenUrlAbstract/FREE Full Text
    1. Ho JS,
    2. Cannaday JJ,
    3. Barlow CE,
    4. et al
    . Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol 2008; 102: 689–692.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Thomas GN,
    2. Phillips AC,
    3. Carroll D,
    4. et al
    . The metabolic syndrome adds utility to the prediction of mortality over its components: the Vietnam Experience Study. Atherosclerosis 2010; 210: 256–261.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Bruce KD,
    2. Byrne CD
    . The metabolic syndrome: common origins of a multifactorial disorder. Postgrad Med J 2009; 85: 614–621.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Drager LF,
    2. Bortolotto LA,
    3. Maki-Nunes C,
    4. et al
    . The incremental role of obstructive sleep apnoea on markers of atherosclerosis in patients with metabolic syndrome. Atherosclerosis 2010; 208: 490–495.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Trombetta IC,
    2. Somers VK,
    3. Maki-Nunes C,
    4. et al
    . Consequences of comorbid sleep apnea in the metabolic syndrome–implications for cardiovascular risk. Sleep 2010; 33: 1193–1199.
    OpenUrlPubMedWeb of Science
  7. ↵
    1. Levy P,
    2. Bonsignore MR,
    3. Eckel J
    . Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34: 243–260.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. McNicholas WT,
    2. Bonsigore MR
    . Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29: 156–178.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Jun J,
    2. Polotsky VY
    . Metabolic consequences of sleep-disordered breathing. ILAR J 2009; 50: 289–306.
    OpenUrlPubMedWeb of Science
  10. ↵
    1. Tasali E,
    2. Ip MS
    . Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 2008; 5: 207–217.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Batsis JA,
    2. Romero-Corral A,
    3. Collazo-Clavell ML,
    4. et al
    . Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc 2008; 83: 897–907.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Soverini V,
    2. Moscatiello S,
    3. Villanova N,
    4. et al
    . Metabolic syndrome and insulin resistance in subjects with morbid obesity. Obes Surg 2010; 20: 295–301.
    OpenUrlCrossRefPubMed
  13. ↵
    1. O'Keeffe T,
    2. Patterson EJ
    . Evidence supporting routine polysomnography before bariatric surgery. Obes Surg 2004; 14: 23–26.
    OpenUrlPubMedWeb of Science
  14. ↵
    1. Sareli AE,
    2. Cantor CR,
    3. Williams NN,
    4. et al
    . Obstructive sleep apnea in patients undergoing bariatric surgery – a tertiary center experience. Obes Surg 2011; 21: 316–327.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Gold PM
    . The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care 2009; 54: 1040–1049.
    OpenUrlPubMedWeb of Science
  16. ↵
    1. Craig CL,
    2. Marshall AL,
    3. Sjostrom M,
    4. et al
    . International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381–1395.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Marin R,
    2. de la Sierra A,
    3. Armario P,
    4. et al
    . [2005 Spanish guidelines in diagnosis and treatment of arterial hypertension]. Med Clin (Barc) 2005; 125: 24–34.
    OpenUrlCrossRefPubMed
  18. ↵
    Sleep-related breathing disorders in adults. recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667–689.
    OpenUrlPubMedWeb of Science
  19. ↵
    1. Matthews DR,
    2. Hosker JP,
    3. Rudenski AS,
    4. et al
    . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Wilson PW,
    2. D'Agostino RB,
    3. Levy D,
    4. et al
    . Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Salord N,
    2. Mayos M,
    3. Miralda R,
    4. et al
    . Respiratory sleep disturbances in patients undergoing gastric bypass surgery and their relation to metabolic syndrome. Obes Surg 2009; 19: 74–79.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Coughlin SR,
    2. Mawdsley L,
    3. Mugarza JA,
    4. et al
    . Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735–741.
    OpenUrlAbstract/FREE Full Text
    1. Gruber A,
    2. Horwood F,
    3. Sithole J,
    4. et al
    . Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 5: 22.
    OpenUrlCrossRefPubMed
  23. ↵
    1. McArdle N,
    2. Hillman D,
    3. Beilin L,
    4. et al
    . Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007; 175: 190–195.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Tkacova R,
    2. Dorkova Z,
    3. Molcanyiova A,
    4. et al
    . Cardiovascular risk and insulin resistance in patients with obstructive sleep apnea. Med Sci Monit 2008; 14: CR438–CR444.
    OpenUrlPubMedWeb of Science
  25. ↵
    1. Drager LF,
    2. Lopes HF,
    3. Maki-Nunes C,
    4. et al
    . The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One 2010; 5: e12065.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Drager LF,
    2. Genta PR,
    3. Pedrosa RP,
    4. et al
    . Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol 2010; 105: 1135–1139.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Takama N,
    2. Kurabayashi M
    . Relationship between metabolic syndrome and sleep-disordered breathing in patients with cardiovascular disease–metabolic syndrome as a strong factor of nocturnal desaturation. Intern Med 2008; 47: 709–715.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Bixler EO,
    2. Vgontzas AN,
    3. Lin HM,
    4. et al
    . Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163: 608–613.
    OpenUrlCrossRefPubMedWeb of Science
    1. Young T,
    2. Finn L,
    3. Austin D,
    4. et al
    . Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 2003; 167: 1181–1185.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Shahar E,
    2. Redline S,
    3. Young T,
    4. et al
    . Hormone replacement therapy and sleep-disordered breathing. Am J Respir Crit Care Med 2003; 167: 1186–1192.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Lam JC,
    2. Lam B,
    3. Lam CL,
    4. et al
    . Obstructive sleep apnea and the metabolic syndrome in community-based Chinese adults in Hong Kong. Respir Med 2006; 100: 980–987.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Ip MS,
    2. Lam B,
    3. Ng MM,
    4. et al
    . Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670–676.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Bradley TD,
    2. Floras JS
    . Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009; 373: 82–93.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Calhoun DA,
    2. Jones D,
    3. Textor S,
    4. et al
    . Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510–e526.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Young T,
    2. Peppard P,
    3. Palta M,
    4. et al
    . Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 1997; 157: 1746–1752.
    OpenUrlCrossRefPubMedWeb of Science
    1. Nieto FJ,
    2. Young TB,
    3. Lind BK,
    4. et al
    . Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829–1836.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Lavie P,
    2. Herer P,
    3. Hoffstein V
    . Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479–482.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Reichmuth KJ,
    2. Austin D,
    3. Skatrud JB,
    4. et al
    . Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005; 172: 1590–1595.
    OpenUrlCrossRefPubMedWeb of Science
    1. Punjabi NM,
    2. Beamer BA
    . Alterations in glucose disposal in sleep-disordered breathing. Am J Respir Crit Care Med 2009; 179: 235–240.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Steiropoulos P,
    2. Papanas N,
    3. Bouros D,
    4. et al
    . Obstructive sleep apnea aggravates glycemic control across the continuum of glucose homeostasis. Am J Respir Crit Care Med 2010; 182: 286.
    OpenUrlPubMed
  38. ↵
    1. Kono M,
    2. Tatsumi K,
    3. Saibara T,
    4. et al
    . Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007; 131: 1387–1392.
    OpenUrlCrossRefPubMedWeb of Science
    1. Minoguchi K,
    2. Yokoe T,
    3. Tazaki T,
    4. et al
    . Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 625–630.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Tan KC,
    2. Chow WS,
    3. Lam JC,
    4. et al
    . HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006; 184: 377–382.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Newman AB,
    2. Nieto FJ,
    3. Guidry U,
    4. et al
    . Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001; 154: 50–59.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Roche F,
    2. Sforza E,
    3. Pichot V,
    4. et al
    . Obstructive sleep apnoea/hypopnea influences high-density lipoprotein cholesterol in the elderly. Sleep Med 2009; 10: 882–886.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Jun J,
    2. Polotsky VY
    . Sleep disordered breathing and metabolic effects: evidence from animal models. Sleep Med Clin 2007; 2: 263–277.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Louis M,
    2. Punjabi NM
    . Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J Appl Physiol 2009; 106: 1538–1544.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Polotsky VY,
    2. Patil SP,
    3. Savransky V,
    4. et al
    . Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 2009; 179: 228–234.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Bazzano LA,
    2. Khan Z,
    3. Reynolds K,
    4. et al
    . Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007; 50: 417–423.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Lam JC,
    2. Lam B,
    3. Yao TJ,
    4. et al
    . A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J 2010; 35: 138–145.
    OpenUrlAbstract/FREE Full Text
    1. West SD,
    2. Nicoll DJ,
    3. Wallace TM,
    4. et al
    . Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969–974.
    OpenUrlAbstract/FREE Full Text
    1. Coughlin SR,
    2. Mawdsley L,
    3. Mugarza JA,
    4. et al
    . Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007; 29: 720–727.
    OpenUrlAbstract/FREE Full Text
    1. Vgontzas AN,
    2. Zoumakis E,
    3. Bixler EO,
    4. et al
    . Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest 2008; 38: 585–595.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Drager LF,
    2. Jun J,
    3. Polotsky VY
    . Obstructive sleep apnea and dyslipidemia: implications for atherosclerosis. Curr Opin Endocrinol Diabetes Obes 2010; 17: 161–165.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Basta M,
    2. Vgontzas AN
    . Metabolic abnormalities in obesity and sleep apnea are in a continuum. Sleep Med 2007; 8: 5–7.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Garvey JF,
    2. Taylor CT,
    3. McNicholas WT
    . Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009; 33: 1195–1205.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Fruhbeck G,
    2. Gomez-Ambrosi J,
    3. Muruzabal FJ,
    4. et al
    . The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280: E827–E847.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Duren DL,
    2. Sherwood RJ,
    3. Czerwinski SA,
    4. et al
    . Body composition methods: comparisons and interpretation. J Diabetes Sci Technol 2008; 2: 1139–1146.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Vgontzas AN,
    2. Papanicolaou DA,
    3. Bixler EO,
    4. et al
    . Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 1151–1158.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    1. Vgontzas AN,
    2. Bixler EO,
    3. Tan TL,
    4. et al
    . Obesity without sleep apnea is associated with daytime sleepiness. Arch Intern Med 1998; 158: 1333–1337.
    OpenUrlCrossRefPubMedWeb of Science
  54. ↵
    1. Vgontzas AN,
    2. Tan TL,
    3. Bixler EO,
    4. et al
    . Sleep apnea and sleep disruption in obese patients. Arch Intern Med 1994; 154: 1705–1711.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Bixler EO,
    2. Vgontzas AN,
    3. Lin HM,
    4. et al
    . Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab 2005; 90: 4510–4515.
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    1. Basta M,
    2. Lin HM,
    3. Pejovic S,
    4. et al
    . Lack of regular exercise, depression, and degree of apnea are predictors of excessive daytime sleepiness in patients with sleep apnea: sex differences. J Clin Sleep Med 2008; 4: 19–25.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 5 Table of Contents
European Respiratory Journal: 38 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Obstructive sleep apnoea and metabolic impairment in severe obesity
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Obstructive sleep apnoea and metabolic impairment in severe obesity
M. Gasa, N. Salord, A.M. Fortuna, M. Mayos, N. Vilarrasa, J. Dorca, J.M. Montserrat, M.R. Bonsignore, C. Monasterio
European Respiratory Journal Nov 2011, 38 (5) 1089-1097; DOI: 10.1183/09031936.00198810

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Obstructive sleep apnoea and metabolic impairment in severe obesity
M. Gasa, N. Salord, A.M. Fortuna, M. Mayos, N. Vilarrasa, J. Dorca, J.M. Montserrat, M.R. Bonsignore, C. Monasterio
European Respiratory Journal Nov 2011, 38 (5) 1089-1097; DOI: 10.1183/09031936.00198810
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Sleep medicine
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Article

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Spirometer controlled cine-MRI and TBM in paediatric patients
  • Prior CV disease and mortality COPD pneumonia patients
Show more Original Article

Sleep-Related Disorders

  • SDB in patients receiving buprenorphine/naloxone therapy
  • Detection of OSA by an electronic nose
  • Respiratory OSA event lengths in patients with heart failure
Show more Sleep-Related Disorders

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society